Valuation: AnaptysBio, Inc.

Market Cap 1.97B 1.72B 1.6B 1.47B 2.78B 188B 2.83B 19.03B 7.46B 92.39B 7.38B 7.22B 319B P/E 2026 *
-268x
P/E 2027 * 16.7x
Enterprise Value 1.87B 1.64B 1.52B 1.4B 2.65B 179B 2.7B 18.14B 7.11B 88.06B 7.04B 6.88B 304B EV / Sales 2026 *
17x
EV / Sales 2027 * 10.9x
Free-Float
94.32%
Yield 2026 *
-
Yield 2027 * -
1 day+3.97%
1 week+11.47%
Current month+2.90%
1 month+16.72%
3 months+1.06%
6 months+44.33%
Current year+43.28%
1 week 60.94
Extreme 60.94
69.99
1 month 55.16
Extreme 55.16
69.99
Current year 42
Extreme 42
73.3
1 year 17.11
Extreme 17.1062
73.3
3 years 12.21
Extreme 12.21
73.3
5 years 12.21
Extreme 12.21
73.3
10 years 10
Extreme 10
134
Manager TitleAgeSince
Chief Executive Officer 46 2022-03-20
Director of Finance/CFO 42 2026-05-10
Corporate Officer/Principal 35 2021-12-31
Director TitleAgeSince
Director/Board Member 79 2015-06-29
Director/Board Member 63 2015-06-29
Director/Board Member 49 2021-04-07
Date Insider Type Main position Quantity % Market Cap.
06-14Fiscal year

Director

12,060 0.0414%
06-14Fiscal year

Chairman

12,060 0.0414%
06-14Fiscal year

Director

12,060 0.0414%
Change 5-day change 1-year change 3-year change Capi.($)
+3.97%+11.47%+157.74%+273.44% 1.97B
-2.48%-3.13%+55.85%+89.65% 54.88B
-0.55%-6.57%+55.85%+128.31% 54.63B
-5.50%-2.51%+6.73%+418.57% 25.06B
-1.68%-4.32%-19.03%-17.93% 23.14B
-1.69%-0.64%+40.04%-0.48% 19.87B
+1.87%+4.16%+38.74%-26.42% 17.55B
-2.72%-0.60%+187.08%+351.91% 16.5B
-2.42%+1.00%+48.24%+635.77% 15.75B
-0.88%+0.50%+22.44%+188.42% 14.2B
Average -1.20%-0.27%+59.37%+204.13% 24.35B
Weighted average by Cap. -1.77%-1.51%+48.43%+166.56%

Financials

2026 *2027 *
Net sales 110M 96.47M 89.35M 82.21M 156M 10.53B 159M 1.06B 418M 5.17B 413M 404M 17.85B 154M 135M 125M 115M 217M 14.7B 221M 1.49B 583M 7.22B 577M 564M 24.94B
Net income -7.47M -6.55M -6.07M -5.58M -10.56M -715M -10.76M -72.3M -28.36M -351M -28.04M -27.43M -1.21B 129M 113M 105M 96.21M 182M 12.32B 186M 1.25B 489M 6.05B 483M 473M 20.89B
Net Debt -92.22M -80.89M -74.92M -68.93M -130M -8.83B -133M -893M -350M -4.33B -346M -339M -14.97B -293M -257M -238M -219M -414M -28.05B -422M -2.84B -1.11B -13.77B -1.1B -1.08B -47.57B
Logo AnaptysBio, Inc.
AnaptysBio, Inc. is a royalty management company. The Company manages the financial collaborations for Jemperli with GlaxoSmithKline (GSK) and imsidolimab with Vanda Pharmaceuticals Inc. (Vanda). The Company's financial collaboration with GSK is focused upon the development and commercialization of Anaptys-discovered Jemperli (dostarlimab), a PD-1 antagonist, approved for endometrial cancer and dMMR pan tumors, and is being studied in rectal cancer, colon cancer and head and neck squamous cell carcinoma. The Company's financial collaboration with Vanda is focused upon the development and commercialization of Anaptys-discovered imsidolimab, an IL-36R antagonist, which is being developed for generalized pustular psoriasis (GPP).
Employees
104
Date Price Change Volume
26-07-13 US$69.25 +4.30% 512,406
26-07-10 US$66.39 -0.30% 401,063
26-07-09 US$66.59 +1.90% 394,336
26-07-08 US$65.35 -2.93% 1,164,820
26-07-07 US$67.33 +8.05% 947,775
Trader
Investor
Global
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
66.39USD
Average target price
87.09USD
Spread / Average Target
+31.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ANAB Stock